Ifosfamide-induced nephrotoxicity in oncological patients.
Juan Eduardo Quiroz-AldaveMaría Del Carmen Durand-VasquezFreddy Shanner Chávez-VásquezAlexandra Noelia Rodríguez-AnguloSonia Elizabeth Gonzáles-SaldañaCarlos César Alcalde-LoyolaJulia Cristina Coronado-ArroyoFrancisca Elena Zavaleta-GutiérrezLuis Alberto Concepción-UrteagaJuan Carlos Haro-VarasMarcio José Concepción-ZavaletaPublished in: Expert review of anticancer therapy (2023)
Ifosfamide remains essential in neoplasm treatment, but nephrotoxicity, often compounded by coadministered drugs, poses diagnostic challenges. Preventive strategies are lacking, necessitating further research. Identifying timely risk factors can mitigate renal damage, and a multidisciplinary approach manages established nephrotoxicity. Emerging therapies may reduce ifosfamide induced nephrotoxicity.
Keyphrases
- drug induced
- risk factors
- high glucose
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- oxidative stress
- peritoneal dialysis
- endothelial cells
- prognostic factors
- prostate cancer
- rectal cancer
- patient reported outcomes
- low grade
- radical prostatectomy
- combination therapy
- replacement therapy